



HOW TO BECOME A GLOBAL LEADER

INVESTOR PRESENTATION, JANUARY 2022




INVESTOR PRESENTATION, JANUARY 2022

FOCUS POINTS OF EQUITY STORY

- Founded in 1997, the Vita 34 Group today is the leading cell bank in Europe with around 850.000 total cell storages and clients from more than 20 countries
- Pioneering the cord blood banking industry in Europe, Vita 34 constantly invests in R&D and thus opens new business opportunities (e.g. Adipose Tissue, Immune Cells, SVF)
- In addition to organic growth, since 2010 the Company pursues a substantial growth track via M&A, successfully acquiring and integrating a total of seven competitors throughout Europe
- In 2021 Vita 34 and its European peer PBKM/ FamiCord agree to join forces under the umbrella of Vita 34 with its strategically ideal set-up in DACH
- The combined entity is by far the largest cell bank
 in Europe and the 3rd largest worldwide

Vita 34 - pure growth from day 1 Development of total cell storages



ViTA34

GENERAL BUSINESS MODEL – STORAGE PROCESS



Present process from customer acquisition to storage, adaptable also for new product segments

					*
1.	2.	3.	4.	5.	6.
Information via doctors, midwives, health insurances or Internet	Order via Internet, contract, medical history, shipping of collection kit	Collection in partner hospitals and clinics	Shipping to Vita 34 within max. 72 hours	Processing in the laboratory, analysis and preparation of storage	Storage in controlled process at -180° C

INVESTOR PRESENTATION, JANUARY 2022

GENERAL BUSINESS MODEL – CRITICAL SUCCESS FACTORS

High Market Coverage

- High market coverage of clinics
 (e.g. Germany ~90% of maternity clinics)
- Market partnerships provide further upside (e. g. B2B, National Cell Banks)

Comprehensive Knowledge of GMP Processes

- Each process step certified by relevant authorities
- Certification processes of 24 36 months keeping "adventurers" off the market
- ✓ FACT-NetCord accreditation

Sophisticated Technology

- High cell yield
- Autologous and allogenic use
- Technology transfer is key to new products

Innovative Product Pipeline

- ✓ New products in Cell Banking well on track
- ✓ Strong track record in certification processes
- Strong cash flow provides convenient R&D environment for Vita 34

BUSINESS COMBINATION WITH PBKM – FORGING THE FUTURE GLOBAL LEADER



2017 – 2020 Occasional talks between Vita 34 and PBKM

31 May 2021

Vita 34 and PBKM sign business combination agreement

20 September 2021 Start of public exchange offer for PBKM shares

18 November 2021 Transaction settlement

7 July 2020 Anchor Investor of PBKM acquires >30% of Vita 34 shares

13 July 2021 Vita 34 AGM resolves capital increase

28. October 2021 High acceptance rate


of exchange offer of ~98%

Next steps

- Raise revenue & cost synergies in the combined new Group
- Full integration of both brands (Vita 34 & FamiCord) into combined Group until end of 2023
- Maximize operational excellence and streamline increased growth potential
- Total transaction cost: ~ EUR 3.5 million

BUSINESS COMBINATION WITH PBKM – MERGER BENEFITS






Strong unified German presence

- **Cross selling** via access to experimental therapies in EU (Poland) to Vita clients and leveraging PBKM's experience in therapies and CDMO on German market
- Shared experiences with contract renewals Process optimization - Joint competence centers and intra-group services
- Focus on market growth instead of mutual competition
 New business initiatives such as ATMP and CAR-T cell therapies, extensive investment already made
 Joint R&D roadmap to leverage know-how to further expand business (e.g. viral vectors, for cell therapies)
- **Cost optimization** via optimized use of current structures Sufficient back-up capacities for further growth
- Benefit from joint consumer-directed marketing skillset
- Sharing best experience from various markets

EUROPEAN MARKET COVERAGE OF THE COMBINED ENTITY


- Business combination forges clearly dominant
 European market leader
- Perfect match:
 only ~15% overlap in operational business
- Operationally ideal setup: main activities in the heart of Europe
- Strong cash flow from operations as basis for accelerated organic & inorganic growth
- Finalization of industry consolidation in Europe as clear strategic target within max. 5 years
- Market intruders will be kept off European market by aggressive pricing strategies, if necessary
- First operations out of Europe:
 Middle East & Hong Kong as bridgeheads



VITA34


NEW STORAGES, RECURRING REVENUES & HIGH IMPACT OF CONTRACT RENEWALS






- Simplified illustration of revenue streams
- ✓ About 70% of customers choose up-front payment (\rightarrow one-time revenue) vs. 30% yearly payment contracts (\rightarrow recurring revenue)
- Up-front payment contract usually have a fixed term of 20 to 25 years
- Renewals of contracts increase high-margin revenues
- ✓ Only about 5 percent of of clients decide not to renew contracts: very low customer lifetime churn rate!
- ✓ With start of contract renewal phase: exponential growth of recurring revenues lead to exponential growth of cash flows form existing customer base!

Due to maturity of business model: high number of contract renewals starting from 2021



DEVELOPMENT OF REVENUES AND EBITDA





Revenues (in mEUR)

* Aggregate mid-ranges of former official revenues guidances of Vita 34 and PBKM combined

* Reported EBITDA adjusted for special items from transaction costs


** Aggregate mid-ranges of former official EBITDA guidances of Vita 34 and PBKM combined adjusted for special items from transaction costs and special items from investments into R&D



FROM CELL STORAGE TO DRUG INNOVATION: ATMP-HE AND UNIQUE THERAPY DEVELOPMENT




Complementary R&D projects form basis for vast new business opportunities



NEW GROUP WITH EVEN BROADER CELL-ORIENTED PORTFOLIO



From perinatal focus to comprehensive service provider in personalized medicine






- 2021 forecast cancelled in November 2021 against background of business combination
- Unchanged positive development of operating business; however, in the absence of consolidated business figures for the new Group as a whole, no realistic forecast possible for 2021
- Forecast for fiscal year 2022 upon presentation of consolidated figures in Q1 2022
- Dividend payment by Annual General Meeting 2020 suspended against background of COVID-19
- Future dividend payments to be reviewed against background of accelerated growth path

PERSPECTIVE UNTIL 2026 – MID-TERM DEVELOPMENT POTENTIAL



Following VISION 2021, the **PERSPECTIVE 2026**** draws the big picture of the company's strategic approach for the next 5 years....





* Aggregated average of the last official forecasts of Vita 34 and PBKM combined.

** Revenue outlook 2026 is dependent on numerous external factors and therefore not an official forecast / financial projection!

POTENTIAL NOT YET REFLECTED IN SHARE PRICE DEVELOPMENT







* SB member F. Schuhbauer is a shareholder of AOC Health GmbH

Key facts		Analyst coverage	Analyst coverage		
ISIN	DE000A0BL849	Montega Research, Henrik Markmann	BUY, PT 21.00		
Segment	Prime Standard	Warburg Research, Cansu Tatar	tba, PT tba		
Shares outstanding	16,036,459				

INVESTOR PRESENTATION, JANUARY 2022



TECHNOLOGICAL APPENDIX

NEW PRODUCT "IMMUNE CELLS" & ECONOMIC RATIONAL






Rationale behind the new product

- Cryo-preservation of immune cells from peripheral blood offers the chance of conserving immune cells for everybody
- GMP process (blood sampling, transport, processing & cryo-conservation) is similar to already established GMP process for cord blood processing, approval and permission process "manageable"
- Successful medical treatments with immune cells by 3rd party pharmaceutical companies will rapidly increase public awareness of new medical benefits from immune cell storages
- ✓ High potential **Synergies from existing customers** (90% of customers "highly interested" in immune cell storage)

FACTORS AFFECTING CAR-T PRODUCT QUALITY




Early collection, processing & storage improve CAR-T quality

optimization of starting material quality, standardization of processing

IMMUNE CELL THERAPIES – A BIG STEP TOWARDS "PERSONALIZED MEDICINE"





Increasing impact in anti-cancer therapies

CAR-T Immunotherapies approved by FDA and EMA

Kymriah® (Novartis), Yescarta® (Gilead), TecartusTM (Gilead) liso-cel (Juno Therapeutics, approval expected)

400+ experimental therapies in clinical research

CASE STUDY: NEW GROWTH INITIATIVES SIGNIFICANT REVENUE AND EARNINGS POTENTIAL



CELL & GENE THERAPIES

BIOLOGICAL AGENTS (VIRAL VECTORS)

- ✓ B2B sale of stem cell lines to researching pharma companies, both for research grade and manufacturing / GMP grade
- ✓ Viral vectors demand growing at 13% p.a. driven by new gene therapy products and viral vaccines expanding
- Market value of viral vectors estimated at EUR 0.4 bn in 2020 and expected to reach EUR 0.7-0.9bn in 2025

Potential for Vita 34

- Niche occupation potential: Majority of players specialized in 2-4 types of vectors
- ✓ Potential 2-3 % market share → Revenues of EUR 15-25m

PHARMA CDMO (CONTRACTING BUSINESS)

- CDMO positioning as reliable development and manufacturing partner of cell and gene therapeutical products
- ✓ CAGR of market value expected to reach ~40% driven by increasing number of marketed therapies.
- ✓ Global demand to increase from EUR 1.5- 2.0bn in 2020 to EUR 3.0-5.0bn in 2025

Potential for Vita 34

- Lag of capacities in Europe leads to significant undersupply of cell therapy manufacturing
- ✓ Potential 0.5-1% market share → Revenues of EUR 15-30m

Experience with obtaining GMP certifications from various regulatory bodies
 Own established ATMP production with over 1.500 treated patients
 Access to labour at lower cost than in current cell & gene therapies

perfectly positioned!



Contact:

Vita 34 AG

Ingo Middelmenne Investor Relations Perlickstraße 5 04103 Leipzig Tel. +49 341 48792 7574 Fax +49 341 48792 39 E-Mail: ingo.middelmenne@vita34.de www.vita34.de

